




RealRate

MEDICINAL PRODUCTS 2021



MyMD Pharmaceuticals Inc.
Rank 23 of 52





RealRate

MEDICINAL PRODUCTS 2021

MyMD Pharmaceuticals Inc. Rank 23 of 52



The relative strengths and weaknesses of MyMD Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyMD Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 205% points. The greatest weakness of MyMD Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 116% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	36,843
Assets, Non-Current	0
General and Administrative Expense	4,322
Goodwill	0
Liabilities, Current	2,263
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-5,295
Other Revenues	0
Property, Plant and Equipment, Net	0
Research and Development	7,964

Output Variable	Value in 1000 USD
Liabilities	2,263
Assets	36,843
Expenses	12,286
Revenues	0
Stockholders Equity	34,579
Net Income	-17,581
Comprehensive Net Income	-17,581
Economic Capital Ratio	60%